Predictive Oncology (NASDAQ: POAI) CEO Joins NNW Podcast to Discuss Company’s Prospects; Provides Update on POAI Subsidiaries

Nov 11, 2020

  • Predictive Oncology CEO Carl Schwartz featured on NNW’s podcast to discuss the company’s prospects
  • Schwartz elaborated on company’s various divisions, affirming that POAI had begun to see revenue trends stabilize, cash burn rates decline
  • TumorGenesis received overwhelmingly positive feedback on its initial product launches, with plans to extend its technological prowess to address other oncological segments
  • Soluble Biotech, which announced its first major contract in August, is expected to reveal news of second order win in near future
  • Schwartz touched upon POAI’s Helomics business, stating his belief that division could soon transition towards monetizing its unique and one-of-a-kind asset portfolio

Predictive Oncology (NASDAQ: POAI) CEO Carl Schwartz was recently featured in an exclusive audio interview with NetworkNewsWire (“NNW”), a financial news and content distribution company, to provide an update on the company’s recent milestones and near-term goals following the October release of his open letter to Predictive Oncology’s shareholders (https://ibn.fm/XLY14). During the wide-ranging conversation, Schwartz sought to update listeners on the company’s subsidiaries – Skyline Medical, TumorGenesis, Soluble Biotech and Helomics (https://ibn.fm/Vqkh5).

Schwartz commenced by outlining the status of the company’s Skyline Medical business, charged with overseeing the manufacture and sale of their proprietary STREAMWAY system – designed to provide medical facilities with. . .

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

MORE NEWS
RECOMMENDED

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

SainsKini is established to address and cover all notable science and technology discoveries made in the region and properly credit them for the whole world to acknowledge.